MNOV (MediciNova) Change In Receivables: $-0.38 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNOV MediciNova Inc MNOV
29 GF Score
Price $1.29
! 2 Warning Signs
View Full Analysis

What is MediciNova Change In Receivables?

MediciNova MNOV -3.01% 29 Change In Receivables is $-0.38 Mil as of Mar. 2026. GuruFocus rates MNOV with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

MediciNova's change in receivables for the quarter that ended in Mar. 2026 was $-0.25 Mil. It means MediciNova's Accounts Receivable increased by $0.25 Mil from Dec. 2025 to Mar. 2026 .

MediciNova's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means MediciNova's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

MediciNova's Accounts Receivable for the quarter that ended in Mar. 2026 was $0.25 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. MediciNova's Days Sales Outstanding for the three months ended in Mar. 2026 was 119.55.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. MediciNova's liquidation value for the three months ended in Mar. 2026 was $24.21 Mil.

MediciNova  (NAS:MNOV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

MediciNova's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.245/0.187*91
=119.55

2. In Ben Graham's calculation of liquidation value, MediciNova's accounts receivable are only considered to be worth 75% of book value:

MediciNova's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=27.329-3.298+0.75 * 0.245+0.5 * 0
=24.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediciNova Change In Receivables Related Terms

MediciNova Change In Receivables Historical Data

* Premium members only.

The historical data trend for MediciNova's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediciNova Change In Receivables Chart

MediciNova Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MediciNova Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.14 0.00 0.00 -0.25
MNOV
29GF Score
MediciNova Inc MNOV
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediciNova Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.38 Mil mean?
MediciNova (MNOV) has a Change In Receivables of $-0.38 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for MediciNova and its competitors.
Is MediciNova's Change In Receivables too high?
MediciNova's current Change In Receivables is $-0.38 Mil. Overall, MediciNova has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's Change In Receivables compare to CRDF and PMVP?
MediciNova's Change In Receivables of $-0.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for MediciNova and its competitors. MediciNova's current Change In Receivables is $-0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (MNOV) has a current Change In Receivables of $-0.38 Mil. The current Change In Receivables is $-0.38 Mil. MediciNova's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For MediciNova (MNOV), the current Change In Receivables is $-0.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediciNova Business Description

Other Exchanges 4875:Japan
Address 4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
29GF Score

Get the complete analysis for MNOV

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.29
Price